Abstract
Wolff-Parkinson-White Syndrome (WPW) is a rare ventricular pre-excitation syndrome due to the presence of an atrioventricular accessory pathway. WPW patients are prone to fatal arrhythmias. Antipsychotics are FDA-approved for various psychiatric illnesses which increases the possibility of patients with WPW receiving such medications. Currently, there is scarce evidence on the safety of antipsychotics in WPW patients.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
